Aduro Biotech appoints Natalie Sacks as chief medical officer
Prior to joining Aduro, Dr. Sacks served as an advisor on development strategy for multiple firms.
Previously, she was vice president of Clinical Development at Onyx Pharmaceuticals where she played a key role in the development and approval of Kyprolis and in business development strategy.
Prior to that, she served as vice president of Clinical Research for Exelixis where she directed the development of a portfolio of small molecules, ranging from IND filing to late-stage development, including Cometriq.
Earlier in her career, she held positions of increasing responsibility at Cell Genesys, culminating as vice president of Clinical Development.
Prior to her tenure in biotechnology, she served in a variety of research and analytical roles at academic institutions and companies including Massachusetts General Hospital, Medical College of Pennsylvania, and ICI-Stuart Pharmaceuticals.
In addition to her industry experience, Dr. Sacks holds an active faculty appointment at the University of California, San Francisco (UCSF) where she is an assistant clinical professor of medicine in the Division of Hematology/Oncology.
She received her M.D. from the University of Pennsylvania School of Medicine, her M.S. in Biostatistics from Harvard University School of Public Health and her B.A. in Mathematics from Bryn Mawr College. ■
LATEST MOVES FROM California
- Peregrine Pharmaceuticals appoints Mark R. Bamforth to boards
- Endologix appoints John Onopchenko as COO
- Depomed appoints Santosh J. Vetticaden as CSO
- Wells Fargo names Michael Roemer as chief compliance officer
- ARMO BioSciences appoints Joseph Leveque as CMO
More inside POST
Lamprell saw profit in H1 Earnings